Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report.

Hamza FNM, Eltayeb F, Al Katari M, Ibrahim MFK

Open source

DOI
10.3390/curroncol33080476
Published
2026 Aug 13
Container
Current oncology (Toronto, Ont.)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/curroncol33080476,
  title = {Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report.},
  author = {Hamza FNM and Eltayeb F and Al Katari M and Ibrahim MFK},
  year = {2026},
  journal = {Current oncology (Toronto, Ont.)},
  doi = {10.3390/curroncol33080476},
  url = {https://doi.org/10.3390/curroncol33080476}
}

RIS

TY  - JOUR
TI  - Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report.
AU  - Hamza FNM
AU  - Eltayeb F
AU  - Al Katari M
AU  - Ibrahim MFK
PY  - 2026
JO  - Current oncology (Toronto, Ont.)
DO  - 10.3390/curroncol33080476
UR  - https://doi.org/10.3390/curroncol33080476
ER  - 

APA

FNM, H., F, E., M, A. K., & MFK, I. (2026). Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report.. Current oncology (Toronto, Ont.). https://doi.org/10.3390/curroncol33080476

Source records